Investigating the role of minichromosome maintenance protein 2 in differentiating follicular adenoma from follicular carcinoma of thyroid

Mahmood Akhavan Tafti, Zahra Kargar, Shokouh Taghipour zahir, Mehrdad Roozbeh, Somayeh Zabihi Mahmoodabadi, Aliasghar Kheirkhah Vakilabad, Farzan Safi Dahaj


Thyroid nodules are often discovered incidentally in the clinical practice. Even though definite preoperative diagnosis of follicular thyroid lesions prevents unnecessary thyroid surgeries, fine needle aspiration (FNA) cannot definitely differentiate benign or malignant follicular lesions of the thyroid. Several proliferative markers including minichromosome maintenance proteins (MCM) have been evaluated for diagnosis of follicular lesion. In this study, the immunohistochemical expression of MCM2 in follicular adenoma and carcinoma of thyroid was investigated to determine whether it can distinguish between them and if there is a difference between follicular carcinomas diagnosed with capsular/vascular invasion. The correlation between intensity of MCM2 expression in follicular adenoma and carcinoma was evaluated. Thirty cases of follicular carcinoma and thirty cases of follicular adenoma were obtained from pathology department in Yazd, Iran from 2005 to 2015. We subdivided the follicular carcinomas into three groups on the basis of vascular and capsular invasion. The data were analyzed using SPSS v. 16 and p-value<0.05 was considered meaningful. In this study, the average intensity of MCM2 expression was 73.16% in adenoma and 70.31% in carcinoma which was equally distributed in the invasion area of carcinoma and subcapsular area of adenoma. There is no meaningful relationship between marker expression of MCM2 and gender nor age. MCM2 expression in the thyroid follicular carcinoma is not significantly more than the MCM2 expression in follicular adenoma. MCM2 cannot be used for cytology diagnosis before surgical operations nor for confirming or ruling out histopathologic suspicious cases.


Thyroid Carcinomas, Follicular Adenoma, Minichromosome Maintenance Proteins

Full Text:



Popoveniuc G, Jonklaas J. Thyroid nodules. Med Clin North Am 96:329-349, 2012.

Aratake Y, Umeki K, Kiyoyama K, Hinoura Y, Sato S, Ohno A. et al. Diagnostic utility of galectin‐3 and CD26/ DPPIV as preoperative diagnostic markers for thyroid nodules. Diagn Cytopathol 26:366-372, 2002.

Gharib H, Papini E, Paschke R. Thyroid nodules: a review of current guidelines, practices, and prospects. Eur J Endocrinol 159:493-505, 2008.

Shaha AR. Implications of prognostic factors and risk groups in the management of differentiated thyroid cancer. The Laryngoscope 114:393-402, 2004.

McHenry CR, Thomas SR, Slusarczyk SJ, Khiyami A. Follicular or Hürthle cell neoplasm of the thyroid: Can clinical factors be used to predict carcinoma and determine extent of thyroidectomy? Surgery 126:798-804, 1999.

Saleh HA, Jin B, Barnwell J, Alzohaili O. Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules. Diagn Pathol 5:9, 2010.

Bryson PC, Shores CG, Hart C, Thorne L, Patel MR, Richey L. et al. Immunohistochemical distinction of follicular thyroid adenomas and follicular carcinomas. Arch otorhinolaryngol- head neck surg 134:581-586, 2008.

Bartolazzi A, Gasbarri A, Papotti M, Bussolati G, Lucante T, Khan A, et al. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. The Lancet 357:1644-1650, 2001.

Ciaputa R, Nowak M, Kandefer-Gola M, Dziedzic K, Halupka P, Pula B, et al. Morphological and immunohistological characteristics of follicular-compact thyroid carcinoma in dog. Folia Histochem Cytobiol 52:157-161, 2014.

Oestreicher‐Kedem Y, Halpern M, Roizman P, Hardy B, Sulkes J, Feinmesser R, et al. Diagnostic value of galectin‐3 as a marker for malignancy in follicular patterned thyroid lesions. Head & neck 26:960-966, 2004.

Papotti M, Rodriguez J, De Pompa R, Bartolazzi A, Rosai J. Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential. Mod Pathol 18:541-546, 2005.

Tumuluri V, Thomas GA, Fraser IS. Analysis of the Ki‐67 antigen at the invasive tumour front of human oral squamous cell carcinoma. J Oral Pathol Med 3:598-604, 2002.

Bologna-Molina R, Mosqueda Taylor A, Molina Frechero N, Mori Estevez AD, Sánchez Acuña G. Comparison of the value of PCNA and Ki-67 as markers of cell proliferation in ameloblastic tumors. Med Oral Patol Oral Cir Bucal 18:e174-9, 2013.

Akhtar M, Scognamiglio T. Minimally Invasive Follicular Carcinoma Versus Follicular Adenoma: MCM2 Proliferation Marker may be Helpful. Adv Anat Pathol 13:343, 2006.

Freeman A, Morris LS, Mills AD, Stoeber K, Laskey RA, Williams GH, et al. Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. Clin Cancer Res 5:2121-2132, 1999.

Labib, Ramy, and Shiao-yng Chan. Patient with Thyroid Disease: Challenges and Management Options. In: Coomarasamy A, editor. Gynecologic and Obstetric Surgery: Challenges and Management Options, 1st edn. London: John Wiley & Sons; pp 30-32, 2016.

Dean DS, Gharib H. Epidemiology of thyroid nodules. Best Pract Res Clin Endocrinol Metab 22:901-911, 2008.

Ezzat S, Sarti DA, Cain DR, Braunstein GD. Thyroid incidentalomas: prevalence by palpation and ultrasonography. Arch Intern Med 154:1838-1840, 1994.

Tan GH, Gharib H. Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern Med 126:226-231, 1997.

Mahfouz SM, AbdEl-Aal WE, Ali HHM, El-Habashi A, Esmail RSE. Galectin-3 and MCM2 expression in fine-needle aspiration cytology of thyroid nodules and their preoperative role in distinguishing benign from malignant thyroid lesions. Egypt J Pathol 32:245-255, 2012.

Goldstein RE, Netterville JL, Burkey B, Johnson JE. Implications of Follicular Neoplasms, Atypia, and Lesions Suspicious for Malignancy Diagnosed by Fine-Needle Aspiration of Thyroid Nodules. Ann Surg 235:656–664, 2002.

Theodosiou Z, Kasampalidis IN, Livanos G, Zervakis M, Pitas I, Lyroudia K. Automated analysis of FISH and immunohistochemistry images: a review. Cytometry Part A 71:439-450, 2007.

Bilous M, Dowsett M, Hanna W, Isola J, Lebeau A,

Moreno A, Penault-Llorca F, Rüschoff J, Tomasic G, Van de Vijver M. Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol 16:173-182, 2003.

Endl E, Gerdes J. The Ki-67 protein: fascinating forms and an unknown function. Exp Cell Res 257:231-237, 2000.

Mehrotra P, Gonzalez MA, Johnson SJ, Coleman N, Wilson JA, Davies BR, Lennard TW. Mcm‐2 and Ki‐67 Have Limited Potential in Preoperative Diagnosis of Thyroid Malignancy. The Laryngoscope 116:1434-1438, 2006.

Fedchenko N, Reifenrath J. Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue–a review. Diagn Pathol 9:221, 2014.

McHenry CR, Phitayakorn R. Follicular adenoma and carcinoma of the thyroid gland. The Oncologist 16:585–593, 2011.

Going JJ, Keith WN, Neilson L, Stoeber K, Stuart RC, Williams GH. Aberrant expression of minichromosome maintenance proteins 2 and 5, and Ki-67 in dysplastic squamous oesophageal epithelium and Barrett`s mucosa. Gut 50:373-377, 2002.


  • There are currently no refbacks.